- Home
- EVGO vs TNGX Comparison
EVGO vs TNGX Comparison
Compare EVGO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- TNGX
- Stock Information
- Founded
- EVGO 2010
- TNGX 2014
- Country
- EVGO United States
- TNGX United States
- Employees
- EVGO N/A
- TNGX N/A
- Industry
- EVGO Other Specialty Stores
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- TNGX Health Care
- Exchange
- EVGO Nasdaq
- TNGX Nasdaq
- Market Cap
- EVGO N/A
- TNGX 317.4M
- IPO Year
- EVGO N/A
- TNGX N/A
- Fundamental
- Price
- EVGO $2.76
- TNGX $1.76
- Analyst Decision
- EVGO Strong Buy
- TNGX Strong Buy
- Analyst Count
- EVGO 10
- TNGX 7
- Target Price
- EVGO $6.11
- TNGX $12.33
- AVG Volume (30 Days)
- EVGO 3.7M
- TNGX 801.9K
- Earning Date
- EVGO 03-04-2025
- TNGX 05-07-2025
- Dividend Yield
- EVGO N/A
- TNGX N/A
- EPS Growth
- EVGO N/A
- TNGX N/A
- EPS
- EVGO N/A
- TNGX N/A
- Revenue
- EVGO $256,825,000.00
- TNGX $42,069,000.00
- Revenue This Year
- EVGO $42.11
- TNGX N/A
- Revenue Next Year
- EVGO $30.36
- TNGX N/A
- P/E Ratio
- EVGO N/A
- TNGX N/A
- Revenue Growth
- EVGO 59.57
- TNGX 15.17
- 52 Week Low
- EVGO $1.65
- TNGX $1.71
- 52 Week High
- EVGO $9.07
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EVGO 50.16
- TNGX 33.97
- Support Level
- EVGO $2.33
- TNGX $1.80
- Resistance Level
- EVGO $2.82
- TNGX $2.04
- Average True Range (ATR)
- EVGO 0.18
- TNGX 0.18
- MACD
- EVGO 0.07
- TNGX 0.01
- Stochastic Oscillator
- EVGO 90.98
- TNGX 20.19
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.